AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.
Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing etokimab, an antibody that inhibits the activity of interleukin-33, for the treatment of moderate-to-severe adult atopic dermatitis, severe adult eosinophilic asthma, and adult chronic rhinosinusitis with nasal polyps (CRSwNP).
In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).
Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.
Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.
Advancing our lead wholly-owned programs for the treatment of severe inflammatory disease
We plan to develop our proprietary anti-IL-33 antibody (etokimab) for the treatment of severe adult asthma and severe adult peanut allergy. In addition, we intend to develop our anti-IL-36R antibody (ANB019) for the treatment of generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).
Identifying emerging target biology opportunities in inflammation
We intend to remain at the forefront of discovery and development of new therapeutic opportunities in inflammation by understanding and translating biological breakthroughs into first-in-class therapeutic antibodies. Our approach includes assessment of human genetics and tissue pathology to understand the relevance of emerging targets to patients with unmet medical needs. We plan to leverage this knowledge to create new product candidates and position our current and future programs for rapid clinical proof-of-concept achievement.
Expanding our proprietary pipeline by generating new antibody product candidates using our technology platform
Using our proprietary antibody generation platform, we are able to rapidly develop novel therapeutic antibodies against emerging targets. Our goal is to advance multiple additional wholly-owned new therapeutic antibody program to IND submission.
Retaining rights to strategic products in key commercial markets
We intend to retain ownership and control of our pipeline programs to key inflection points. We may build sales and marketing capabilities in selected specialty markets that we believe can be served with a focused commercial organization. For certain programs, we plan to seek strategic collaborations that provide us with funding, infrastructure and marketing resources to advance through development and commercialization.
Management
Hamza Suria
President and CEOHamza Suria was appointed CEO in 2011 and has since led AnaptysBio’s transformation from its early platform technology focus to the development of a robust antibody product pipeline across key therapeutic areas.
+
Marco Londei, M.D.
Chief Medical OfficerMarco Londei, M.D., joined AnaptysBio from Bristol-Myers Squibb (BMS) where he was Therapeutic Area Head, Immunosciences and responsible for early clinical and translational research for a portfolio of immune-related therapeutics.
+
Dominic Piscitelli
Chief Financial OfficerDominic Piscitelli joined AnaptysBio as Chief Financial Officer in January 2017, with more than 15 years of industry experience.
+
Eric Loumeau
General CounselEric Loumeau joined AnaptysBio in August 2018 with more than twenty years of experience in biotech legal affairs.
+
Hemant Kumar, Ph.D.
Senior Vice President, ManufacturingHemant Kumar joined AnaptysBio in November 2017 with more than 20 years of experience in biologicals manufacturing.
+
Margaret Marino, Ph.D.
Vice President, Project ManagementMargaret Marino, Ph.D., joined AnaptysBio from Pfizer, where she was responsible for external R&D innovation and project management across a number of biologics programs within the CovX Biotech Unit.
+
Carolyn Hobbs
Vice President, New Product PlanningCarolyn Hobbs joined AnaptysBio in January 2018 with more than 20 years of experience in marketing, commercialization, and new product planning of novel therapeutic products.
+Board Of Directors
James N. Topper, M.D., Ph.D.
Chairman of AnaptysBio Managing General Partner at Frazier HealthcareJamie Topper, M.D., Ph.D., is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team.
+Hollings Renton
Former President and CEO of Onyx PharmaceuticalsHollings Renton has previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals from 1993 to 2008 and as the Chairman of the Board from 2000 to 2008.
+John Schmid
Former CFO of Auspex PharmaceuticalsJohn Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 until its sale to Teva Pharmaceuticals, Inc. in June 2015. Prior to Auspex, he co-founded Trius Therapeutics, Inc., where he served as Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc.
+Dennis Fenton, Ph.D.
Former Executive Vice President, AmgenDr. Fenton held positions of increasing responsibility at Amgen from 1982 through to his retirement in 2008, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and Executive Vice President.
+Nick Lydon, Ph.D., FRS
Granite Biopharma, LLCNick Lydon, Ph.D., FRS, has extensive experience in drug discovery and development and is a recipient of the Lasker Prize and other awards for his achievements in medicine.
+J. Anthony Ware, M.D.
Former SVP Product Development, Lilly Bio-Medicines, Eli Lilly and CompanyDr. Ware currently serves as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he is responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas.
+Hamza Suria
President and CEO, AnaptysBio, Inc.Hamza Suria was appointed CEO in 2011 and has since led AnaptysBio’s transformation from its early platform technology focus to the development of a robust antibody product pipeline across key therapeutic areas.
+Therapeutic Advisory Board
David L. Lacey, M.D.
Former Senior Vice President and Head of Discovery Research at AmgenDavid L. Lacey, M.D., is a former Senior Vice President and Head of Discovery Research at Amgen with over 30 years of basic and clinical research experience.
+Michael Gallatin, Ph.D.
Former Vice President and Scientific Director of ICOS CorporationMichael Gallatin, Ph.D., is a former Vice President and Scientific Director of ICOS Corporation, where his responsibilities included discovery, preclinical research, medicinal chemistry and process chemistry groups, including those responsible for worldwide development and launch of Tadalafil (Cialis®).
+Jan de Vries, Ph.D.
Former Head of the Novartis Research Institutes for BioMedical ResearchJan de Vries, Ph.D., is the former Head of the Novartis Research Institutes for BioMedical Research in Basel, Switzerland. Prior to that, he was Head of the Novartis Research Institute in Vienna and Global Head of the Disease Area Autoimmunity, Transplantation and Inflammation.
+Nick Lydon, Ph.D., FRS
Granite BiopharmaNick Lydon, Ph.D., FRS, has extensive experience in drug discovery and development and is a recipient of the Lasker Prize and other awards for his achievements in medicine.
+